microdosing glp-1 drugs What is Microdosing? - Chronic Illness Support Groups & Resources Microdosing GLP-1: Should You Try

DTC portals for drugs are a solution to a problem that wouldnt exist if insurer coverage were better

What is it and what are the pros and cons?

People are losing 15, 20 percent of their body weight

Exposures Two cohorts were assembled, with the first composed of patients who started and continued on GLP-1 receptor agonists or DPP-4 inhibitors between 1 January 2007 and 31 December 2020 and the second composed of patients who started and continued on GLP-1 receptor agonists or SGLT-2 inhibitors between 1 January 1 2013 and 31 December 2020

By Sabina Paglialunga, PhD & Aernout van Haarst, PhD Senior Directors Scientific Affairs Glucagon-Like Peptide-1 (GLP-1) receptor agonists first came to the market in 2005 as a type 2 diabetes mellitus treatment, and they have been making headlines again for their weight reduction effects